Skip to content

Clinical trials

Overweight trials in South Korea

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Overweight Country / region: South Korea Clear all

51 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20105
20131
20141
20161
20172
20183
20191
20202
20212
20221
20234
20245
20258
202613

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed22
Recruiting16
Active, not recruiting5
Unknown status3
Not yet recruiting2
Enrolling by invitation2
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company11
Novo Nordisk A/S8
Amgen4
Seoul National University Hospital4
AstraZeneca2
Gangnam Severance Hospital2
Hoffmann-La Roche2
Pusan National University Yangsan Hospital2
Yonsei University2
Bristol-Myers Squibb1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Overweight51
Obesity44
Diabetes Mellitus, Type 214
Diabetes Mellitus3
Body Weight2
Body Weight Changes2
Nutrition Disorders2
Overnutrition2
Atherosclerosis1
Bipolar Disorder1

Trials

Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.